Protea Biosciences Group, Inc. 4

Accession 0001144204-14-008841

CIK 0001335103operating

View on SEC.gov Company Profile

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 9:37 PM ET

Size

31.1 KB

Accession

0001144204-14-008841

Insider Transaction Report

Form 4

Period: 2006-06-07

Protea Biosciences Group, Inc.NONE

TURNER STEPHEN C

DirectorCEO and Chairman of the Board

Transactions

Purchase
Common Stock
2013-07-30$112102.00/sh+224,204$25,133,716,808→ 2,153,372 total
Purchase
Common Stock
2013-07-30$112102.00/sh+224,204$25,133,716,808→ 2,153,372 total(indirect: By Spouse)
Award
Stock Option
2006-06-07$80000.00/sh+100,000$8,000,000,000→ 216,668 total
Exercise: $0.80From: 2006-06-07Exp: 2016-06-07→ Common Stock (100,000 underlying)
Award
Stock Option
2010-04-23$360938.00/sh+240,625$86,850,706,250→ 457,293 total
Exercise: $1.50From: 2010-04-23Exp: 2020-04-23→ Common Stock (240,625 underlying)
Purchase
Convertible Note
2012-04-16$100000.00/sh+200,000$20,000,000,000→ 657,293 total
Exercise: $0.50From: 2012-04-16Exp: 2013-05-31→ Common Stock
Purchase
Convertible Note
2012-04-16$100000.00/sh+200,000$20,000,000,000→ 657,293 total(indirect: By Spouse)
Exercise: $0.50From: 2012-04-16Exp: 2013-05-31→ Common Stock
Purchase
Convertible Note
2012-09-25$20000.00/sh+40,000$800,000,000→ 697,293 total
Exercise: $0.50From: 2012-09-25Exp: 2013-12-31→ Common Stock
Purchase
Convertible Note
2012-09-25$20000.00/sh+40,000$800,000,000→ 697,293 total(indirect: By Spouse)
Exercise: $0.50From: 2012-09-25Exp: 2013-12-31→ Common Stock
Purchase
Warrant
2013-07-29$184968.00/sh+168,153$31,102,924,104→ 865,446 total
Exercise: $1.10From: 2018-07-29Exp: 2018-07-29→ Common Stock
Purchase
Warrant
2013-07-29$184968.00/sh+168,153$31,102,924,104→ 865,446 total(indirect: By Spouse)
Exercise: $1.10From: 2018-07-29Exp: 2018-07-29→ Common Stock
Conversion
Convertible Note
2013-07-30$112102.00/sh−224,204$25,133,716,808→ 508,778 total
Exercise: $0.50From: 2013-07-30Exp: 2013-07-30→ Common Stock
Conversion
Convertible Note
2013-07-30$112102.00/sh−224,204$25,133,716,808→ 508,778 total(indirect: By Spouse)
Exercise: $0.50From: 2013-07-30Exp: 2013-07-30→ Common Stock

Footnotes (7)

[F1]On April 16, 2012, the company issued to Stephen Turner's wife, Nancy Turner, a promissory noted in the principal amount of $100,000 to accrue simple interest at the rate of ten percent (10%) per annum (the "April Note"). The April Note accrues simple interest at 10% per annum and was initially convertibleed into shares of common stock at $2.00 per share. On March 22, 2013, the board of directors of the Company agreed to reduce the conversion rate of the April Note to $0.50 per share. The April Note was converted into shares of common stock of the Company in accordance with the Conversion Agreement described below on June 30, 2013. Nancy Turner converted the outstanding principal and interest due and payable on the April Note and the September Note equal to $112,102 into 224,204 shares of common stock.
[F2]Represents the securities of the Company owned of record jointly by Stephen Turner and his wife, Nancy Turner.
[F3]On September 25, 2012, the company issued a convertible promissory note to Stephen and Nancy Turner in the principal amount of $20,000 (the "September Note") The September Note was initially convertible into shares of common stock of the Company at a conversion rate of $2.00 per share. On March 22, 2013, the board of directors of the Company agreed to reduce the conversion rate of the April Note to $0.50 per share. On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013 (the "Conversion Agreement")
[F4]Pursuant to the Conversion Agreement, upon conversion of the April Note and the September Note, the Company agreed to issue a five-year warrant to purchase 75% of the number of shares into which the April Note and the September Note were collectively convertible into.
[F5]Represents warrants to purchase up to 284,821 shares of common stock jointly held by Stephen Turner and Nancy Turner and 300,000 shares of common stock to be acquired upon the exercise of stock options.
[F6]Represents shares vested as of February 10, 2014.
[F7]Reflects the expiration of previously reported warrants to purchase 116,668 shares of common stock held by the Reporting Person.

Documents

1 file

4
v368338_4.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Protea Biosciences Group, Inc.

CIK 0001335103

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001335103

Filing Metadata

Form type: 4
Filed: Feb 12, 7:00 PM ET
Accepted: Feb 13, 9:37 PM ET
Size: 31.1 KB

View on SEC.gov